Recently, eight chikungunya cases were reported from various European countries and Israel, all returning from Thailand between November 2018 and February 2019 [1] . Here, we report a cluster of five chikungunya cases among 11 family members visiting Koh Lanta, an island district in Krabi Province, in the south of Thailand, in January 2019. Three of the eight cases in the earlier report had visited the same destination as this family [1] .
Case description
A vacation was taken by a group comprising 11 relatives in four family units: family one (adult family members 1-2), family two (adult family members 3-4 and children family members 5-6), family three (family members 7-8); family four (family members 9-11), resided at the same hotel in a popular tourist destination Koh Lanta, Thailand from mid-January 2019, having meals together. The ages of the family members ranged from 9 to 70 years, nine were adults, five were male. Their holiday trips were planned to last 1 or 2 weeks; family 4 returned to Finland after 1 week as scheduled.
On day 9 of their stay, family 2 (members 3-6) spent the evening on the beach practicing sports, while families 1 and 3 only visited the beach briefly. The following day, members of the local population mentioned that there had been an unusually high number of mosquitoes, a 'mosquito invasion', the evening before. Family members 3-6 had applied mosquito repellents that morning and reported only a few bites, while family member 1 had not used any repellent and reported 60-70 mosquito bites all over his legs. Family members 3-6 and family member 1 all fell ill 4-6 days later (days 23-25 of stay in Thailand) with a systemic febrile disease and arthralgias. A description of the cases (in the order of symptom onset) can be seen in Table 1 .
Family 2 was scheduled to return home after a stay of 14 days, but due to the severity of disease in the children (family members 5 and 6), the flight was postponed by 1 week. On return to Finland, the children were further hospitalised. On 1 March (38 days after presumed transmission), the children are back at school with minor arthralgias remaining. Family member 1 continues to have severe polyarthralgia and arthritis, but cannot use nonsteroidal anti-inflammatory drugs (NSAIDs) due to other medications, and has therefore been referred to a rheumatologist. Family member 3 has asthma as underlying disease; while her condition improved with a low dose etoricoxib (30 mg OD), higher doses resulted in an allergic reaction. Referral to a rheumatologist is planned if further clinical improvement under ibuprofen therapy (600 mg TD) is not observed. Family member 4 has arthralgia, but he manages on ibuprofen medication.
Discussion
Febrile systemic diseases in Thailand are not as common as other travel-related health problems like diarrhoea [2, 3] , but often are more severe. Febrile systemic diseases include a large variety of mosquito-borne infections such as malaria, lymphatic filariasis and viral infections caused by Japanese encephalitis, zika, dengue and chikungunya viruses [4, 5] . Prevention of these diseases relies heavily on mosquito avoidance, as vaccines are currently only available for Japanese encephalitis [5] . Chikungunya virus (CHIKV) is transmitted, like dengue and zika viruses, by Aedes aegypti and Aedes albopictus mosquitoes [4, 5] and has an incubation period of 3-7 days, symptoms beginning with an abrupt onset of fever followed by a predominating symptom of severe, sometimes disabling, polyarthralgia [6] . Some patients also develop a rash [6] .
High attack rates of chikungunya pose a risk for tourists in areas where there is local transmission. Travellers can act as sentinels of outbreaks in a region. The cluster we present here accords with the findings by Javelle et al. [1] concerning Geosentinel sites describing a peak in chikungunya cases among visitors to Thailand. Of particular interest in our cluster is the high attack rate -with five of 11 travellers contracting chikungunya, all among the eight who stayed for longer than 1 week.
If, on return to their home countries, travellers are still viraemic and Aedes vectors prevail in their home country, there could be a risk of disease spread. Ae. albopictus appears to be the main vector for most of the European Union and European Economic Area, with Madeira as an exception since it also has an established Ae. aegypti population [7] . Aedes mosquitoes are only found in certain parts of central and southern Europe and the transmission period depends on temperature, usually not beginning before late spring [8] .
In our cluster, four of the five cases had to be hospitalised in Thailand and one of the children required treatment in an intensive care unit. Severe manifestations and even deaths are seen in outbreaks, mostly among the elderly or those with underlying diseases [6] . Indeed, in our cluster, the two children had the 
Evaluation on 1 March (day 34):
Started on day 13 after symptom onset with etoricoxib low dose (30 mg), gradually increasing to 90 mg, then rash; now receiving ibuprofen, walking difficulties, will be referred to a rheumatologist unless starts to improve soon. most severe clinical picture in the acute phase and recovered fairly rapidly, whereas the symptoms persist longer among the adults: now, 6 weeks after the presumed transmission, the two children are nearly asymptomatic, while the three adults still have arthalgias/arthritis, for two of them incapacitating.
In one adult case, an underlying disease prevents the use of NSAIDs for post-acute chikungunya. Antirheumatic medications such as methotrexate and hydroxychloroquine are recommended alternatives, if the NSAIDs cannot be used [9] ; while corticosteroids should not be taken in the acute phase, they may be needed in the chronic stage. Despite treatment, however, severe joint problems may continue for months or even years [6] .
While travellers may act as sentinels of outbreaks in a destination, the peak observed in chikungunya cases in Thailand [1] calls for enhanced prevention also among forthcoming travellers. There is no vaccine available against chikungunya, and mosquito avoidance remains the sole preventive approach. Indeed, it also protects against dengue and zika viruses transmitted by the same mosquito species; even co-infections have been described [10, 11] . Many travellers use mosquito repellents especially at dusk and dawn, the time malariatransmitting Anopheles mosquitoes bite. However, since the Aedes mosquitoes mostly bite in the daytime [4, 8] , to shield themselves against chikungunya, dengue and zika viruses, travellers should also be advised to apply repellents during the day.
Thailand is a popular tourist destination in the world: in 2017 there were over 35 million visitors, 6.5 million arriving from Europe [12] . Many travellers to Thailand do not seek pre-travel advice [13] and it is thus a challenge reach them. Travel agencies, insurance companies and other actors outside the medical community should be approached as additional channels to reach out to tourists and deliver relevant information.
